S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Price, News & Analysis

$2.14
-0.17 (-7.36%)
(As of 04/12/2024 ET)
Today's Range
$2.04
$2.42
50-Day Range
$2.05
$3.24
52-Week Range
$0.70
$3.40
Volume
7.55 million shs
Average Volume
9.32 million shs
Market Capitalization
$396.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33

Esperion Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
336.1% Upside
$9.33 Price Target
Short Interest
Bearish
11.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
-0.11mentions of Esperion Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to $0.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

302nd out of 923 stocks

Pharmaceutical Preparations Industry

133rd out of 427 stocks

ESPR stock logo

About Esperion Therapeutics Stock (NASDAQ:ESPR)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR Stock Price History

ESPR Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up to $2.88
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Esperion Therapeutics Inc.
11 Best Small Cap Pharma Stocks to Invest In
Q4 2023 Esperion Therapeutics Inc Earnings Call
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/13/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$16.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+336.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-209,250,000.00
Net Margins
-179.87%
Pretax Margin
-179.87%

Debt

Sales & Book Value

Annual Sales
$116.33 million
Book Value
($3.85) per share

Miscellaneous

Free Float
183,943,000
Market Cap
$396.01 million
Optionable
Optionable
Beta
0.84
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Sheldon L. Koenig (Age 58)
    President, CEO & Director
    Comp: $1.2M
  • Mr. Benjamin O. Looker (Age 42)
    General Counsel
    Comp: $550.35k
  • Dr. JoAnne Micale Foody FACC (Age 58)
    M.D., Chief Medical Officer
    Comp: $771.19k
  • Mr. Benjamin Halladay M.B.A. (Age 38)
    Chief Financial Officer
  • Mr. Glenn P. Brame (Age 66)
    Chief Technical Operations Officer
  • Tiffany Aldrich M.B.A.
    Associate Director of Corporate Communications
  • Ms. Betty Jean Swartz
    Chief Business Officer
  • Mr. Eric J. Warren R.Ph. (Age 52)
    Chief Commercial Officer

ESPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings
or view top-rated stocks.

What is Esperion Therapeutics' stock price target for 2024?

5 brokerages have issued 1-year price targets for Esperion Therapeutics' shares. Their ESPR share price targets range from $4.00 to $16.00. On average, they anticipate the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 336.1% from the stock's current price.
View analysts price targets for ESPR
or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2024?

Esperion Therapeutics' stock was trading at $2.99 on January 1st, 2024. Since then, ESPR shares have decreased by 28.4% and is now trading at $2.14.
View the best growth stocks for 2024 here
.

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 19,920,000 shares, an increase of 12.7% from the March 15th total of 17,670,000 shares. Based on an average daily volume of 6,710,000 shares, the days-to-cover ratio is presently 3.0 days. Approximately 11.8% of the shares of the company are short sold.
View Esperion Therapeutics' Short Interest
.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ESPR earnings forecast
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.03. The biopharmaceutical company earned $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period last year, the firm posted ($0.76) EPS.

What ETFs hold Esperion Therapeutics' stock?

ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Jacob Forward ETF (JFWD).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Advisors Wealth Management LLC (0.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ESPR) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners